RT Journal Article
T1 Photobiomodulation for the prevention of oral side effects secondary to head and neck cancer therapy: results of a randomised, single-blind clinical trial
A1 Vianna Camolesi, Gisela Cristina
A1 Prado Pena, Irene Beatriz
A1 Gómez Caamaño, Antonio
A1 Victoria Fernández, Concepción
A1 Blanco Carrión, Andrés
A1 García García, Abel
A1 Gándara Vila, Pilar
A1 Pérez-Sayáns García, Mario
K1 Oral mucositis
K1 Dysgeusia
K1 Hyposalivation
K1 Photobiomodulation therapy
K1 Toxicity
K1 Supportive cancer care
AB IntroductionA significant increase of 61.6 % in new cases of head and neck cancer (HNC) worldwide is projected by 2050. Multimodal treatments for HNC often result in debilitating oral side effects like oral mucositis (OM). Photobiomodulation (PBM) therapy shows promise in managing these side effects, yet standardized protocols are lacking. This randomized clinical trial aims to evaluate PBM’s effectiveness in preventing and treating oral side effects and related symptoms in HNC patients.MethodsWe compared PBM with standard treatment in HNC patients at a single centre. PBM efficacy was evaluated on OM, pain, dysgeusia, hyposalivation, dry mouth, and trismus. Additionally, we controlled for analgesic use and fungal infection presence. The study adhered to the CONSORT checklist, is registered on the ClinicalTrials platform, and statistical analysis was performed using SPSS.ResultsThe study included 53 patients. The PBM group experienced a significant reduction in OM progression, better salivary function preservation, and lower severity of pain and dysgeusia by the end of treatment. However, no significant differences were found between the PBM and standard treatment groups regarding xerostomia, trismus, analgesic use, or oral candidiasis incidence.ConclusionPBM showed effectiveness in delaying onset and reducing the severity of oral mucositis and hyposalivation, as well as alleviating pain and dysgeusia at critical moments. However, it had no significant impact on xerostomia, trismus, analgesic use, or oral candidiasis.
PB Elsevier
SN 1368-8375
YR 2025
FD 2025-05
LK https://hdl.handle.net/10347/43433
UL https://hdl.handle.net/10347/43433
LA eng
NO Vianna Camolesi, G. C., Prado-Pena, I. B., Gómez-Caamaño, A., Victoria-Fernández, C., Blanco-Carrión, A., García-García, A., Gándara-Vila, P., & Pérez-Sayáns, M. (2025). Photobiomodulation for the prevention of oral side effects secondary to head and neck cancer therapy: results of a randomised, single-blind clinical trial. Oral Oncology, 164, 107266. 10.1016/j.oraloncology.2025.107266
DS Minerva
RD 28 abr 2026